vTv Therapeutics (NASDAQ: VTVT) is one of 296 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare vTv Therapeutics to related businesses based on the strength of its valuation, analyst recommendations, earnings, profitability, dividends, risk and institutional ownership.


This table compares vTv Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
vTv Therapeutics -13,635.29% N/A -33.58%
vTv Therapeutics Competitors -5,489.25% -451.68% -42.65%

Analyst Ratings

This is a summary of current ratings and recommmendations for vTv Therapeutics and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
vTv Therapeutics 0 0 4 0 3.00
vTv Therapeutics Competitors 766 3044 11232 227 2.72

vTv Therapeutics currently has a consensus target price of $16.50, indicating a potential upside of 151.14%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 35.86%. Given vTv Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe vTv Therapeutics is more favorable than its rivals.

Valuation and Earnings

This table compares vTv Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
vTv Therapeutics $119,000.00 -$52.99 million -3.91
vTv Therapeutics Competitors $260.16 million $66.28 million -6.36

vTv Therapeutics’ rivals have higher revenue and earnings than vTv Therapeutics. vTv Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

11.1% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 0.8% of vTv Therapeutics shares are owned by company insiders. Comparatively, 16.4% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

vTv Therapeutics has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, vTv Therapeutics’ rivals have a beta of 6.62, meaning that their average share price is 562% more volatile than the S&P 500.


vTv Therapeutics rivals beat vTv Therapeutics on 7 of the 12 factors compared.

vTv Therapeutics Company Profile

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.

Receive News & Stock Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related stocks with our FREE daily email newsletter.